- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial2015 | Publication without faculty affiliation
- Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer2019 | First Faculty of Medicine
- Neurobiology, Functions, and Relevance of Excitatory Amino Acid Transporters (EAATs) to Treatment of Refractory Epilepsy2020 | First Faculty of Medicine
- Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up2018 | Publication without faculty affiliation
- Determination of receptor protein binding site specificity and relative binding strength using a time-resolved competition assay2014 | Faculty of Pharmacy in Hradec Králové